Efficacy of pegylated liposomal doxorubicin (PLD) plus carboplatin in ovarian cancer patients who recur within six to twelve months: A phase II study

Keyphrases

• Phase II Study 100%
• Recurring 100%
• Carboplatin 100%
• Ovarian Cancer Patients 100%
• Pegylated Liposomal Doxorubicin 100%
• Platinum Sensitivity 33%
• Carboplatin-paclitaxel 33%
• Disease Stabilization 33%
• Chemotherapy 16%
• Median Time 16%
• Adverse Effects 16%
• Response Rate 16%
• Phase II Trial 16%
• Median Overall Survival 16%
• Thrombocytopenia 16%
• Time to Progression 16%
• Neutropenia 16%
• Initial Treatment 16%
• Efficacy Analysis 16%
• Constipation 16%
• Platinum-based Chemotherapy 16%
• Platinum-resistant Ovarian Cancer 16%
• Objective Response Rate 16%
• 6-cycles 16%
• Optimal Therapy 16%
• Carbohydrate Antigen 125 (CA125) 16%
• Early Relapse 16%

Pharmacology, Toxicology and Pharmaceutical Science

• Ovary Cancer 100%
• Carboplatin 100%
• Doxorubicin 100%
• Disease 28%
• Chemotherapy 28%
• Paclitaxel 28%
• Adverse Event 14%
• Overall Survival 14%
• Phase II Trials 14%
• Thrombocytopenia 14%
• Neutropenia 14%
• Constipation 14%

Medicine and Dentistry

• Platinum-Sensitive Ovarian Cancer 14%